| Ticker | DNLI |
|---|---|
| ISIN | US24823R1059 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which...
Denali Therapeutics Inc. opera en el sector Healthcare, industria Biotechnology.